File Download
  Patent History
  • Application
    US 12/637097 2009-12-14
  • Publication
    US 2010310578 2010-12-09
  Patent Family
Supplementary

published patent: USE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET

TitleUSE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET
Priority Date2009-12-14 US 12/637097
2007-10-19 US 11/875271
2006-10-20 US 11/853404P
Inventors
Xu, AWang, YLam, KSL
Issue Date2010
Citation
US Published patent application US 2010310578. Washington, DC: US Patent and Trademark Office (USPTO), 2010 How to Cite?
AbstractMethods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist.
Persistent Identifierhttp://hdl.handle.net/10722/177004

 

DC FieldValueLanguage
dc.date.accessioned2012-11-30T08:38:55Z-
dc.date.available2012-11-30T08:38:55Z-
dc.date.issued2010-
dc.identifier.citationUS Published patent application US 2010310578. Washington, DC: US Patent and Trademark Office (USPTO), 2010en_HK
dc.identifier.urihttp://hdl.handle.net/10722/177004-
dc.description.abstractMethods and compositions for identifying and treating obesity and obesity-induced metabolic disorders are provided. One aspect provides a method for the evaluation of risk and progression of glucose tolerance, insulin resistance and Type 2 diabetes in mammalian subjects. The method includes measuring the concentration of circulating lipocalin-2 in a subject and comparing the measured level to lipocalin-2 to a reference level. Another aspect provides methods of treating insulin resistance, type 2 diabetes and other related complications by administering to a patient a composition that can reduce the circulating levels of lipocalin-2, for example a lipocalin-2 antagonist.en_HK
dc.titleUSE OF LIPOCALIN-2 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGETen_HK
dc.typePatenten_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorXu, Aen_HK
dc.contributor.inventorWang, Yen_HK
dc.contributor.inventorLam, KSLen_HK
patents.identifier.applicationUS 12/637097en_HK
patents.description.assigneeUNIV HONG KONGen_HK
patents.description.countryUnited States of Americaen_HK
patents.date.publication2010-12-09en_HK
patents.identifier.hkutechidMedi-2006-00232-2-
patents.date.application2009-12-14en_HK
patents.date.priority2009-12-14 US 12/637097en_HK
patents.date.priority2007-10-19 US 11/875271en_HK
patents.date.priority2006-10-20 US 11/853404Pen_HK
patents.description.ccUSen_HK
patents.identifier.publicationUS 2010310578en_HK
patents.relation.familyUS 2008095782 (A1) 2008-04-24en_HK
patents.relation.familyUS 7645616 (B2) 2010-01-12en_HK
patents.relation.familyUS 2010310578 (A1) 2010-12-09en_HK
patents.relation.familyWO 2008049330 (A1) 2008-05-02en_HK
patents.description.kindA1en_HK
patents.typePatent_publisheden_HK

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats